Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab

Leukemia and Lymphoma

Volumn 49, Issue 3, 2008, Pages 462-469

  Ngo, Lynette ^a   Hee, Siew Wan ^a   Lim, Lay Cheng ^b   Tao, Miriam ^a   Quek, Richard ^a   Yap, Swee Peng ^a   Loong, Er Li ^a   Sng, Ivy ^b   Hwan Cheong, Tan Leonard ^b   Ang, Mei Kim ^a   Ngeow, Joanne ^a   Tham, Chee Kian ^a   Tan, Min Han ^a   Lim, Soon Thye ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Diffuse large B cell lymphoma; Prognostic factors; Rituximab

Indexed keywords

ALBUMIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC VALUE; DRUG USE; FEMALE; GENDER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 39749180292     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701809156     Document Type: Article

References (13)

1. DeVita Jr, V. T., Canellos, G. P. and Chabner, B. (1975) Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet, 1, pp. 248-250.
2. Schein, P. S., DeVita Jr, V. T. and Hubbard, S. (1976) Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisolone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med, 85, pp. 417-422.
3. Fisher, R. I., DeVita Jr, V. T. and Johnson, B. L. (1977) Prognostic factors in advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med, 63, pp. 177-182.
4. Gayner, E. R., Ultmann, J. E. and Golomb, H. M. (1985) Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, Oncovin, methotrexate, leucovorin, cytosine arabinoside): A 10-year experience in a single institution. J Clin Oncol, 3, pp. 1596-1604.
5. Coltman, C. A., Dahlberg, S. and Jones, S. E. (1988) Southwest Oncology Group studies in diffuse large cell lymphoma: A subset analysis. Cancer Chemotherapy: Challenges for the Future, pp. 194-202. Excerpta Medica, Tokyo
6. Fisher, R. I., Gaynor, E. R. and Dahlberg, S. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimes for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, pp. 1002-1006.
7. Shipp, M. A. (1994) Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease?. Blood, 83, p. 1165.
8. Coiffier, B., Lepage, E. and Briere, J. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med, 346, pp. 235-242.
9. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R. and Fermé, C. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 23, pp. 4117-4126.
10. Sehn, L. H., Berry, B. and Chhanabhai, M. (2007) Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, pp. 1857-1861.
11. Jaffe, E. (2001) Tumours of Hematopoietic and Lymphoid Tissues, IARC Press, Lyon
12. Altman, G. D. (1991) Practical Statistics for Medical Research, Chapman and Hall, London
13. Coiffier, B. (2005) State-of-the-art therapeutics: Diffuse large B-cell lymphoma. J Clin Oncol, 23, pp. 6387-6393.